Aims: Prior studies suggest that autologous bone marrow mononuclear cells (BMCs) implantation improve symptoms and left ventricular (LV) function in patients (pts) with ischemic cardiomyopathy. However, the efficacy of endomyocardial implantation of BMCs in pts with advanced heart failure (HF) is unclear.
plications. In the SHIFT trial, we investigated: 1) the clinical profile and outcomes of patients with CHF and COPD, 2) the efficacy and safety of ivabradine, a heart rate-reducing agent. Methods: 6505 patients, in sinus rhythm, with heart rate ≥70 bpm and stable systolic CHF were randomized to placebo or ivabradine (2.5 to 7.5 mg bid). Multivariate Cox model analyses were performed to compare the COPD (n = 730) and non-COPD subgroups, and the ivabradine and placebo treatment effects in both subgroups. Results: COPD patients were older and had a poorer risk profile. Beta-blockers were prescribed to 69% of COPD patients and 92% of non-COPD patients and daily doses were lower in COPD patients. Primary endpoint (PE) and its components, cardiovascular (CV) death and hospitalisation for worsening heart failure (HF), were more frequent in COPD patients (HR for PE: 1.22, [95% CI 1.06-1.40], P=0.006; CV death: 1.00 [0.82-1.22], P=0.98; HF hospitalisation: 1.34 [1.14-1.57], P=<0.001), but were reduced similarly by ivabradine in both COPD (14%; 24%; 17%) and non-COPD (18%; 7%; 27%) patients (P interaction=0.82; 0.23; 0.53, respectively) . Adverse events (AE) were more common in COPD patients (83% vs 73% in placebo arms), but AE rate was similar in the ivabradine and placebo arms of both subgroups. As expected, symptomatic or asymptomatic bradycardia occurred more frequently with ivabradine, but the incidences in patients with or without COPD were similar. Conclusions: COPD represents a barrier to optimization of beta-blocker therapy in CHF, and the association of COPD and CHF results in a worse prognosis. Ivabradine is similarly effective and safe in CHF patients with or without COPD, and can be safely combined with beta-blockers in COPD.
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Geometry and degree of apposition of a cardiac plug for left atrial appendage occlusion: a multi-slice computer tomography study Purpose: Left atrial appendage (LAA) occlusion is a valuable alternative for stroke prevention in patients with atrial fibrillation. The Amplatzer Cardiac Plug ® (ACP, St. Jude Medical, MN, USA) is a self-expanding device with a disc-lobe configuration. Our aim was to evaluate the geometry and degree of apposition of the ACP with multi-slice computer tomography (MSCT). Methods: Forty-eight patients had a MSCT after LAA occlusion with the ACP at a median 8 months (interquartile range [IQR] 3 to 14 months). Axial dimensions, cross-sectional area (CSA), and perimeter of the ACP disc and ACP lobe (at 3 levels: proximal, median, and distal), and the disc-lobe angulations were evaluated. The % degree of lobe deformation and lobe expansion were assessed. ACP disc and lobe apposition on the LAA walls were evaluated using a clock-face and were correlated to relevant anatomic structures. The causes for non-apposition were also investigated. Patients with signs of device non-apposition on MSCT underwent trans-esophageal echocardiography (TEE) with color-flow Doppler for detection of peri-device leaks.
Results:
The mean ACP size was 23.4±3.2 mm. The mean disc diameter was 28.0±3.9 mm and the mean disc-lobe angulation was 13.3±6.8 degrees. The median (IQR) lobe deformation at the proximal, median, and distal segment was 4.4 (1.9-8.7), 5.9 (3.1-8.7), and 5.3 (3.2-8.6)%, respectively. The degree of lobe expansion at the proximal, median, and distal segment was 96.0±5.0, 94.9±5.9, and 96.2±5.3%, respectively. In 17 patients (35%) some degree of disc and/or lobe non-apposition was found. Non-apposition was associated with lobe expansion (apposition vs non-apposition 93.1±7.2 vs 97.1±2.3%, p<0.05). The causes for non-apposition were device undersizing (7/17 patients, 41%), special LAA -"chicken-wing" anatomy (7/17 patients, 41%), too shallow implant (2/17 patients, 12%), and non-perpendicular lobe position (1/17 patients, 6%). Ten patients (10/17, 60%) had a TEE at a median (IQR) 5 (2-16) months post-procedure. In 7 and 4 patients residual flow was detected around the ACP disc and lobe, respectively. The median (IQR) jet width was 1.8 (0-2.8) mm and the largest jet was 4.3 mm.
Conclusions:
Multi-slice computer tomography demonstrated a 4-6% degree of axial deformation and a 94-96% expansion of the ACP lobe. Non-apposition of the ACP disc and/or lobe was found in one third of patients and was associated with more lobe expansion. Device undersizing and LAA "chicken-wing" anatomy were identified as main causes for non-apposition. None of the patients with device non-apposition had significant peri-device leaks on TEE.
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Transcatheter left atrial appendage occlusion: a 10-year single center experience using Amplatzer devices 
